Background: Patients with chronic kidney disease (CKD) have very high levels of uncarboxylated, inactive, extra-hepatic vitamin K-dependent proteins measured in circulation, putting them at risk for complications of vitamin K deficiency. The major form of vitamin K found in the liver is phylloquinone (K1). Menaquinone-4 (MK-4) is the form of vitamin K that is preferentially found in extra-hepatic tissues. Methods: In the present study, we assessed tissue concentrations of K1 and MK-4 and the expression of vitamin K-related genes in a rat model of adenine-induced CKD. Results: It was found that rats with both mild and severe CKD had significantly lower amounts of K1 measured in liver, spleen and heart and higher levels of MK-4 measured in kidney cortex and medulla. All animals treated with high dietary K1 had an increase in tissue levels of both K1 and MK-4; however, the relative increase in K1 differed suggesting that the conversion of K1 to MK-4 may be a regulated/limiting process in some tissues. There was a decrease in the thoracic aorta expression of vitamin K recycling (Vkor) and utilization (Ggcx) enzymes, and a decrease in the kidney level of vitamin K1 to MK-4 bioconversion enzyme Ubiad1 in CKD. Conclusion: Taken together, these findings suggest that CKD impacts vitamin K metabolism, and this occurs early in the disease course. Our findings that vitamin K metabolism is altered in the presence of CKD provides further support that sub-clinical vitamin K deficiency may represent a modifiable risk factor for vascular and bone health in this population.

1.
Luo G, Ducy P, McKee MD, et al: Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997;386:78-81.
2.
Spronk HM, Soute BA, Schurgers LJ, et al: Matrix Gla protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall. Biochem Biophys Res Commun 2001;289:485-490.
3.
Montezano AC, Zimmerman D, Yusuf H, et al: Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension 2010;56:453-462.
4.
Shanahan CM, Cary NR, Salisbury JR, et al: Medial localization of mineralization-regulating proteins in association with Mönckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation 1999;100:2168-2176.
5.
Schurgers LJ, Spronk HM, Skepper JN, Hackeng TM, Shanahan CM, Vermeer C, Weissberg PL, Proudfoot D: Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. J Thromb Haemost 2007;5:2503-2511.
6.
Schurgers LJ, Barreto DV, Barreto FC, et al: The circulating inactive form of matrix Gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol 2010;5:568-575.
7.
Cranenburg EC, Schurgers LJ, Uiterwijk HH, Beulens JW, Dalmeijer GW, Westerhuis R, Magdeleyns EJ, Herfs M, Vermeer C, Laverman GD: Vitamin K intake and status are low in hemodialysis patients. Kidney Int 2012;82:605-610.
8.
McCabe KM, Booth SL, Fu X, et al: Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int 2013;83:844.
9.
Kaesler N, Magdeleyns E, Herfs M, et al: Impaired vitamin K recycling in uremia is rescued by vitamin K supplementation. Kidney Int 2014;86:286-293.
10.
Holden RM, Iliescu E, Morton AR, et al: Vitamin K status of Canadian peritoneal dialysis patients. Perit Dial Int 2008;28:415-418.
11.
Pilkey RM, Morton AR, Boffa MB, et al: Subclinical vitamin K deficiency in hemodialysis patients. Am J Kidney Dis 2007;49:432-439.
12.
Holden RM, Morton AR, Garland JS, Pavlov A, Day AG, Booth SL: Vitamins K and D status in stages 3-5 chronic kidney disease. Clin J Am Soc Nephrol 2010;5:590-597.
13.
Fusaro M, D'Alessandro C, Noale M, Tripepi G, et al: Low vitamin K1 intake in haemodialysis patients. Clin Nutr 2016;pii:5614(16)30070-X.
14.
Stafford DW: The vitamin K cycle. J Thromb Haemost 2005;3:1873-1878.
15.
Shearer MJ, Newman P: Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis. J Lipid Res 2014;55.
16.
Shearer MJ, Bach A, Kohlmeier M: Chemistry, nutritional sources, tissue distribution and metabolism of vitamin K with special reference to bone health. J Nutr 1996;126(4 suppl):1181S-1186S.
17.
Booth SL, Al Rajabi A: Determinants of vitamin K status in humans. Vitam Horm 2008;78:1-22.
18.
Okano T, Shimomura Y, Yamane M, et al: Conversion of phylloquinone (Vitamin K1) into menaquinone-4 (Vitamin K2) in mice: two possible routes for menaquinone-4 accumulation in cerebra of mice. J Biol Chem 2008;283:11270-11279.
19.
Thijssen HH, Drittij-Reijnders MJ, Fischer MA: Phylloquinone and menaquinone-4 distribution in rats: synthesis rather than uptake determines menaquinone-4 organ concentrations. J Nutr 1996;126:537-543.
20.
Hirota Y, Tsugawa N, Nakagawa K, et al: Menadione (vitamin K3) is a catabolic product of oral phylloquinone (vitamin K1) in the intestine and a circulating precursor of tissue menaquinone-4 (vitamin K2) in rats. J Biol Chem 2013;288:33071-33080.
21.
Al Rajabi A, Booth SL, Peterson JW, et al: Deuterium-labeled phylloquinone has tissue-specific conversion to menaquinone-4 among Fischer 344 male rats. J Nutr 2012;142:841-845.
22.
Nakagawa K, Hirota Y, Sawada N, et al: Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. Nature 2010;468:117-121.
23.
Delmas PD, Wilson DM, Mann KG, et al: Effect of renal function on plasma levels of bone Gla-protein. J Clin Endocrinol Metab 1983;57:1028-1030.
24.
Fusaro M, Crepaldi G, Maggi S, Galli F, D'Angelo A, Calo L, Giannini S, Miozzo D, Gallieni M: Vitamin K, bone fractures, and vascular calcifications in chronic kidney disease: an important but poorly studied relationship. J Endocrinol Invest 2011;34:317-323.
25.
Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL: Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int 2006;70:1358-1366.
26.
Fusaro M, Noale M, Viola V, Galli F, Tripepi G, Vajente N, Plebani M, Zaninotto M, Guglielmi G, Miotto D, et al; VItamin K Italian (VIKI) Dialysis Study Investigators: Vitamin K, vertebral fractures, vascular calcifications, and mortality: vitamin K Italian (VIKI) dialysis study. J Bone Miner Res 2012;27:2271-2278.
27.
Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483; Nutrients 2013;5:4398.
28.
Cranenburg EC, Brandenburg VM, Vermeer C, Stenger M, Muhlenbruch G, Mahnken AH, Gladziwa U, Ketteler M, Schurgers LJ: Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Thromb Haemost 2009;101:359-366.
29.
Shobeiri N, Pang J, Adams MA, et al: Cardiovascular disease in an adenine-induced model of chronic kidney disease: the temporal link between vascular calcification and haemodynamic consequences. J Hypertens 2013;31:160-168.
30.
Price PA, Roublick AM, Williamson MK: Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int 2006;70:1577-1583.
31.
Booth SL, Peterson JW, Smith D, et al: Age and dietary form of vitamin K affect menaquinone-4 concentrations in male Fischer 344 rats. J Nutr 2008;138:492-496.
32.
Carrie I, Portoukalian J, Vicaretti R, et al: Menaquinone-4 concentration is correlated with sphingolipid concentrations in rat brain. J Nutr 2004;134:167-172.
33.
Schurgers LJ, Spronk HM, Soute BA, et al: Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood 2007;109:2823-2831.
34.
Spronk HM, Soute BA, Schurgers LJ, et al: Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. J Vasc Res 2003;40:531-537.
35.
Heresztyn T, Nicholson BC: A colorimetric protein phosphatase inhibition assay for the determination of cyanobacterial peptide hepatotoxins based on the dephosphorylation of phosvitin by recombinant protein phosphatase 1. Environ Toxicol 2001;16:242-252.
36.
Booth SL, Dallal G, Shea MK, et al: Effect of vitamin K supplementation on bone loss in elderly men and women. J Clin Endocrinol Metab 2008;93:1217-1223.
37.
Sadowski JA, Hood SJ, Dallal GE, et al: Phylloquinone in plasma from elderly and young adults: factors influencing its concentration. Am J Clin Nutr 1989;50:100-108.
38.
Gundberg CM, Lian JB, Booth SL: Vitamin K-dependent carboxylation of osteocalcin: friend or foe? Adv Nutr 2012;3:149-157.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.